JP2024515266A5 - - Google Patents
Info
- Publication number
- JP2024515266A5 JP2024515266A5 JP2023561850A JP2023561850A JP2024515266A5 JP 2024515266 A5 JP2024515266 A5 JP 2024515266A5 JP 2023561850 A JP2023561850 A JP 2023561850A JP 2023561850 A JP2023561850 A JP 2023561850A JP 2024515266 A5 JP2024515266 A5 JP 2024515266A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167423 | 2021-04-08 | ||
| EP21167423.9 | 2021-04-08 | ||
| PCT/EP2022/059059 WO2022214517A1 (en) | 2021-04-08 | 2022-04-06 | Anti-c-met antibodies and antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515266A JP2024515266A (ja) | 2024-04-08 |
| JP2024515266A5 true JP2024515266A5 (https=) | 2025-03-12 |
Family
ID=75438640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561850A Pending JP2024515266A (ja) | 2021-04-08 | 2022-04-06 | 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240376214A1 (https=) |
| EP (1) | EP4320152A1 (https=) |
| JP (1) | JP2024515266A (https=) |
| KR (1) | KR20230166099A (https=) |
| CN (1) | CN117157325A (https=) |
| AU (1) | AU2022254291A1 (https=) |
| BR (1) | BR112023020801A2 (https=) |
| CA (1) | CA3214718A1 (https=) |
| CL (1) | CL2023002992A1 (https=) |
| IL (1) | IL306142A (https=) |
| MX (1) | MX2023011929A (https=) |
| WO (1) | WO2022214517A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| WO2024131835A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2575402A1 (en) | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| PT3056203T (pt) | 2010-04-21 | 2018-02-15 | Syntarga Bv | Conjugados de análogos de cc-1065 e ligantes bifuncionais |
| RU2608644C2 (ru) | 2010-11-03 | 2017-01-23 | арДЖЕН-ИКС Н.В. | Антитела против белка рецептора с-мет |
| US20140154251A1 (en) | 2011-10-05 | 2014-06-05 | Samsung Electronics Co., Ltd. | Anti c-met antibody and uses thereof |
| KR101463098B1 (ko) * | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| KR102150616B1 (ko) * | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| SG11201609372UA (en) | 2014-05-22 | 2016-12-29 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| WO2016165580A1 (zh) * | 2015-04-17 | 2016-10-20 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| PL3319597T3 (pl) * | 2015-07-10 | 2021-10-11 | Byondis B.V. | Kompozycje zawierające koniugaty przeciwciało-duokarmycyna |
| CA3026139C (en) | 2016-02-12 | 2023-09-12 | Synthon Biopharmaceuticals B.V. | Selective reduction of cysteine-engineered antibodies |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| HUE054571T2 (hu) * | 2016-09-14 | 2021-09-28 | Merck Patent Gmbh | Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik |
| US11419944B2 (en) | 2016-10-11 | 2022-08-23 | Byondis B.V. | Non-linear self-immolative linkers and conjugates thereof |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| HRP20210922T1 (hr) * | 2016-11-23 | 2021-09-03 | Eli Lilly And Company | Konjugati protutijela protiv met s lijekom |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| US11696958B2 (en) | 2017-05-23 | 2023-07-11 | Byondis B.V. | Dual conjugation process for preparing antibody-drug conjugates |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
| EP3774923A4 (en) * | 2018-03-28 | 2021-12-29 | Mitsubishi Tanabe Pharma Corporation | Drug conjugates of cmet monoclonal binding agents, and uses thereof |
-
2022
- 2022-04-06 BR BR112023020801A patent/BR112023020801A2/pt unknown
- 2022-04-06 JP JP2023561850A patent/JP2024515266A/ja active Pending
- 2022-04-06 MX MX2023011929A patent/MX2023011929A/es unknown
- 2022-04-06 WO PCT/EP2022/059059 patent/WO2022214517A1/en not_active Ceased
- 2022-04-06 EP EP22714223.9A patent/EP4320152A1/en active Pending
- 2022-04-06 US US18/554,339 patent/US20240376214A1/en active Pending
- 2022-04-06 CN CN202280026738.8A patent/CN117157325A/zh active Pending
- 2022-04-06 KR KR1020237036317A patent/KR20230166099A/ko active Pending
- 2022-04-06 IL IL306142A patent/IL306142A/en unknown
- 2022-04-06 AU AU2022254291A patent/AU2022254291A1/en active Pending
- 2022-04-06 CA CA3214718A patent/CA3214718A1/en active Pending
-
2023
- 2023-10-05 CL CL2023002992A patent/CL2023002992A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110240655B (zh) | 抗her2抗体及其缀合物 | |
| JP2022550816A5 (https=) | ||
| JP2022506072A5 (https=) | ||
| JP2019502405A5 (https=) | ||
| RU2016117810A (ru) | Конъюгаты белок-полимер-лекарственное средство | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
| HRP20130903T1 (hr) | Heparin-vezujuä†i epidermalnom äśimbeniku rasta sliäśni vezujuä†i proteini antigena äśimbenika rasta | |
| JP7724866B2 (ja) | 抗体薬物複合体およびその用途 | |
| RU2015144287A (ru) | Составы конъюгата антитело против egfr-лекарственное средство | |
| JP2010535713A5 (https=) | ||
| JP2025507817A5 (https=) | ||
| JP2024536881A5 (https=) | ||
| JP2020504607A5 (https=) | ||
| CA3005294A1 (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| JP2024515536A5 (https=) | ||
| JP2024515266A5 (https=) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2024020436A5 (https=) | ||
| JP2019512210A5 (https=) | ||
| JPWO2021251459A5 (https=) | ||
| JP2025513745A5 (https=) | ||
| RU2023128710A (ru) | Антитела против c-met и коньюгаты антитела с лекарственным средством | |
| JP2024540062A5 (https=) | ||
| JP2022535276A5 (https=) |